Vipivotide tetraxetan (PSMA-617)

98%

  • Product Code: 109904
  CAS:    1702967-37-0
Molecular Weight: 1042.14 g./mol Molecular Formula: C₄₉H₇₁N₉O₁₆
EC Number: MDL Number:
Melting Point: Boiling Point:
Density: Storage Condition: -20°C, airtight, dry
Product Description: Vipivotide tetraxetan (PSMA-617) is primarily used in targeted radionuclide therapy for prostate cancer. It binds specifically to prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. Once bound, it delivers a radioactive isotope, such as lutetium-177, directly to the cancer cells, minimizing damage to surrounding healthy tissues. This makes it an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited therapeutic alternatives. Its precision in targeting cancer cells helps improve outcomes and reduce side effects compared to traditional therapies.
Sizes / Availability / Pricing:
Size (g) Availability Price Quantity
0.005 10-20 days £1,730.20
+
-
Vipivotide tetraxetan (PSMA-617)
Vipivotide tetraxetan (PSMA-617) is primarily used in targeted radionuclide therapy for prostate cancer. It binds specifically to prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. Once bound, it delivers a radioactive isotope, such as lutetium-177, directly to the cancer cells, minimizing damage to surrounding healthy tissues. This makes it an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited therapeutic alternatives. Its precision in targeting cancer cells helps improve outcomes and reduce side effects compared to traditional therapies.
Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Cart

No products

Subtotal: £0.00
£0.00 Total :